Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Show more
Location: 3940 Trust Way, Hayward, CA, 94545, United States | Website: https://benitec.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
359.6M
52 Wk Range
$8.20 - $17.15
Previous Close
$13.70
Open
$13.90
Volume
4,653
Day Range
$13.88 - $14.00
Enterprise Value
257M
Cash
103.6M
Avg Qtr Burn
-4.667M
Insider Ownership
3.12%
Institutional Own.
90.69%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BB-301 Details Oculopharyngeal Muscular Dystrophy | Phase 1/2 Data readout |